Company news
CanSino Biologics, Inc. news in 2025
CanSino Biologics, Inc.'s news releases, calls and decks from 2025, newest first.
Announcement on Voluntary Disclosure of the Initiation of Phase I Clinical Trial of the Adsorbed Acellular Pertussis (Component), Diphtheria and Tetanus, Haemophilus influenzae Type b (Conjugate) – Meningococcal ACYW-135 (Conjugate) Combination Vaccine and the Completion of Enrollment of the First Subject
December 19, 2025
Announcement on Notifying the Creditors of Offsetting Losses with Capital Reserve
November 27, 2025
Announcement on Implementation of Cancellation of Repurchased A-shares
November 26, 2025
Announcement on Voluntary Disclosure of the Initiation of Phase 1 Clinical Trial and Completion of 1st Subject Enrollment for Inhalable Tuberculosis Vaccine (Type 5 Adenovirus Vector) in Indonesia
November 13, 2025
Announcement on Adding Extraordinary Proposal to the 2nd Extraordinary General Meeting in 2025
November 7, 2025
Announcement on Adjusting Matters Related to the 2025 A-share Restricted Stock Incentive Plan
October 27, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
October 23, 2025
Board of Supervisors' Remarks on Publicity of and Verification Opinions on List of Incentive Objects Initially Granted under 2025 A-share Restricted Stock Incentive Plan
October 17, 2025
-- Announcement on Resolutions of the 9th Meeting of the 3rd Board of Supervisors
September 26, 2025
-- Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Tianjin Jurisdiction and Semi-annual Report Performance Briefing
September 2, 2025
-- Announcement on Using Temporarily Idle Raised Funds for Cash Management
August 20, 2025
-- Announcement on Obtaining Notice of Approval for Drug Clinical Trial for Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell)
July 16, 2025
Announcement on the Obtainment of Drug Registration Certificate for 13-valent Pneumococcal Polysaccharide Vaccine (CRM197/Tetanus Toxoid)
June 20, 2025
Announcement on Resolution of the 2024 Annual General Meeting
June 4, 2025
Voluntary Disclosure on the Approval of Clinical Trial for Inhaled Tuberculosis Vaccine (Adenovirus Type 5 Vector) in Indonesia
May 15, 2025
Notice on Convening the 2024 Annual General Meeting
April 29, 2025
Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing
April 22, 2025
Announcement on Renewing Engagement of Accounting Firm
March 25, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 27, 2025
Announcement on Obtaining the Approval Notice for Drug Clinical Trials of Adsorbed Acellular Pertussis (Components), Tetanus, Diphtheria, Haemophilus Influenzae Type b (Conjugate), and Meningococcal Group ACYW135 (Conjugate) Combined Vaccine
February 24, 2025
Announcement on Voluntary Disclosure of Formal Inclusion of the Drug Registration Application for the "Diphtheria, Tetanus and Acellular Pertussis (Component) Combined Vaccine, Adsorbed" for Infants and Young Children in Priority Review Varieties
February 7, 2025
Announcement on Voluntary Disclosure of Acceptance of Drug Registration Application for Adsorbed Tetanus Vaccine
February 6, 2025
Announcement on Annual Earnings Preannouncement for 2024
January 17, 2025